Arkolith/Insider Trading/NAMS/Form 4

Kooij Louise Frederika

Chief Accounting OfficerNewAmsterdam Pharma Co N.V. (NAMS) · full profile →Form 4 · filed Jan 27, 2026
Net Selling
Open-Market Buys
$0
Open-Market Sells
$2.4M
Net Open-Market Flow
-$2.4M
Transactions
8
6 non-derivative · 2 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Jan 26, 2026Option exercise(M)34K$10.90$375K59K
Jan 26, 2026Sell(S)34K$32.77$1.1M25K
Jan 26, 2026Sell(S)309$33.45$10K24K
Jan 23, 2026Option exercise(M)38K$10.90$416K63K
Jan 23, 2026Sell(S)25K$33.44$850K37K
Jan 23, 2026Sell(S)13K$34.37$439K24K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Jan 26, 2026Option exercise(M)34K—$0146K
Jan 23, 2026Option exercise(M)38K—$0180K

Transaction Codes

M
Option exercise / conversion
S
Open-market sale

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001193125-26-025012) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML